Treatment(s) already received-Chemotherapy Posts on Medivizor
Navigation Menu

Treatment(s) already received-Chemotherapy Posts on Medivizor

Evaluating lenalidomide-based regimens for elderly patients with multiple myeloma

Posted by on Oct 30, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study compared different treatment combinations for first-line and maintenance therapies in elderly patients with multiple myeloma (MM). The authors found that first-line MPR was most effective for fit elderly patients, while all patients benefitted from RP maintenance therapy. Some background MM is a complex disease, and...

Read More

Is low dose leucovorin an effective and safe treatment option for colorectal cancer?

Posted by on Jul 30, 2019 in Colorectal cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of low and high dose leucovorin (folinic acid) in the treatment of colorectal cancer. Researchers suggested that low dose leucovorin might be a safe treatment option for these patients. Some background Colorectal cancer is the fourth leading cause of death by cancer. This cancer frequently...

Read More

Searching for patients with triple negative breast cancer to test durvalumab and olaparib

Posted by on Jun 28, 2019 in Breast cancer | 0 comments

In a nutshell This phase 2 study will investigate the safety and effectiveness of olaparib (Lynparza) alone or in combination with durvalumab (Infinzi) in advanced triple negative breast cancer (TNBC). The main outcome will be progression-free survival (PFS). This study is recruiting in Durham, North Carolina, US. The details...

Read More

Searching for patients with lung cancer that cannot be operated on to test durvalumab after chemotherapy and radiation

Posted by on Jun 24, 2019 in Lung cancer | 0 comments

In a nutshell This phase 2 trial will investigate the safety and effectiveness of durvalumab (Imfinzi) in patients with stage III non-small cell lung cancer (NSCLC).  The main outcomes will be the number of treatment-related adverse events (TRAEs) and progression-free survival (PFS).  The details Non-small cell lung cancer (NSCLC)...

Read More

PET scans in determining outcomes for patients with Hodgkin lymphoma treated with chemotherapy

Posted by on May 20, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate the role of positron emission tomography (PET; an imaging technique) in determining the outcomes for patients with Hodgkin lymphoma treated with chemotherapy. This study concluded that negative-PET scans after chemotherapy predict good outcomes for these patients, regardless of stage at...

Read More

Searching for patients with non-small cell lung cancer to trial a new targeted therapy drug

Posted by on May 11, 2019 in Lung cancer | 0 comments

In a nutshell This phase 3 trial will investigate the safety and effectiveness of osimertinib (Tagrisso) after chemoradiation (CR) in non-small cell lung cancer (NSCLC). The main outcome will be progression-free survival (PFS; survival without cancer growing or spreading). The details Non-small cell lung cancer (NSCLC) is the most...

Read More